Eledon Pharmaceuticals Inc (ELDN) — Cash Flow-to-Debt Ratio
Eledon Pharmaceuticals Inc (ELDN) has a Cash Flow-to-Debt Ratio of -0.14x as of December 2025, meaning its operating cash flow of $-14.09 Million could theoretically repay 0% of its total liabilities ($100.82 Million) in one year. See Eledon Pharmaceuticals Inc (ELDN) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Eledon Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Eledon Pharmaceuticals Inc across 14 annual periods. Also explore Eledon Pharmaceuticals Inc net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Eledon Pharmaceuticals Inc (2012–2025)
Year-by-year debt coverage analysis for Eledon Pharmaceuticals Inc. For market capitalisation and broader financial context, see Eledon Pharmaceuticals Inc (ELDN) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.62x | $-62.34 Million | $100.82 Million | ▲ +22.5% |
| 2024 | -0.80x | $-47.27 Million | $59.27 Million | ▲ +14.3% |
| 2023 | -0.93x | $-39.53 Million | $42.48 Million | ▲ +71.8% |
| 2022 | -3.30x | $-28.42 Million | $8.61 Million | ▲ +25.2% |
| 2021 | -4.41x | $-28.91 Million | $6.55 Million | ▼ -91.1% |
| 2020 | -2.31x | $-15.21 Million | $6.59 Million | ▲ +75.6% |
| 2019 | -9.45x | $-13.86 Million | $1.47 Million | ▼ -101.4% |
| 2018 | -4.69x | $-11.89 Million | $2.53 Million | ▲ +54.8% |
| 2017 | -10.38x | $-14.94 Million | $1.44 Million | ▲ +17.5% |
| 2016 | -12.58x | $-36.52 Million | $2.90 Million | ▼ -90.7% |
| 2015 | -6.60x | $-41.24 Million | $6.25 Million | ▼ -32.5% |
| 2014 | -4.98x | $-21.12 Million | $4.24 Million | ▼ -2716.2% |
| 2013 | -0.18x | $-15.48 Million | $87.55 Million | ▲ +1.8% |
| 2012 | -0.18x | $-9.33 Million | $51.86 Million | — |